From GlobeNewswire: 2025-05-13 08:30:00

Intelligent Bio Solutions Inc. (Nasdaq: INBS) reported strong financial results for Q3, with a 20% sequential revenue growth and a 91% year-over-year gross profit growth. Cartridge sales, accounting for 58% of total sales, contributed to the momentum. The company added 35 new accounts, bringing the total active accounts to over 450.

The company also expanded internationally during Q3, focusing on key European markets and enhancing product readiness. Initiatives included multilingual upgrades to drug screening systems and protection of core intellectual property. These efforts support global scalability and drive commercial growth.

Intelligent Bio Solutions Inc. continues to focus on growing cartridge adoption, reducing losses, and enhancing operational efficiency. The company introduced multilingual functionality across its drug screening system and websites for broader international distribution. These efforts lay a strong foundation for sustainable revenue growth.

In terms of marketing updates, the company launched localized websites in Arabic, Spanish, and Italian, activated multi-channel advertising campaigns in the UK and Australia, and showcased its solutions at key events in the UK, USA, and Europe. Sales updates include securing 35 new accounts and expanding access to fingerprint drug testing in Spain and Andorra.

Financially, the company reported total revenues of $0.73 million for Q3, a 20% increase quarter-over-quarter. Gross profits for Q3 were $341,368, a 91% increase year-over-year. Cartridge revenue increased to 58% for the nine months ended March 31, 2025. Total revenue for the nine months was $2.21 million.

The company’s total cash and cash equivalents as of March 31, 2025, were $2.81 million, with shareholders’ equity at $4.94 million. Intelligent Bio Solutions Inc. continues to focus on innovation and expansion, with a strong financial position to support its growth strategy.



Read more at GlobeNewswire:: Intelligent Bio Solutions Announces Fiscal Q3 2025